Keyphrases
Ocrelizumab
100%
Trial Protocol
100%
Phase IV Study
100%
Cello
100%
Radiologically Isolated Syndrome
100%
Multiple Sclerosis
75%
Clinical Trials
25%
Patient's Will
25%
Treatment Decisions
25%
Immunological Biomarkers
25%
Brain Atrophy
12%
Placebo
12%
Early Intervention
12%
B Cells
12%
High-quality Data
12%
Monoclonal Antibody
12%
Autoimmunity
12%
Serum Biomarkers
12%
First-degree Relatives
12%
Multiple Sclerosis Treatment
12%
CNS Lesions
12%
Immune Cells
12%
Disease Course
12%
CD20+
12%
Clinical Evidence
12%
Screening Program
12%
Cognitive Function
12%
Imaging Biomarkers
12%
Progressive multiple Sclerosis
12%
Single-cell RNA Sequencing (scRNA-seq)
12%
Patient-reported Outcomes
12%
Neurological Symptoms
12%
B-cell Depletion
12%
Early multiple Sclerosis
12%
Disease Pathophysiology
12%
Brain Lesions
12%
Symptom Patterns
12%
Randomized Double-blind Placebo-controlled Study
12%
Patient Relatives
12%
CNS Autoimmunity
12%
McDonald Criteria
12%
Dissemination in Space
12%
B Cell Biology
12%
Immune Recovery
12%
Academia-industry Collaboration
12%
Intrathecal Inflammation
12%
Subtle Cognitive Impairment
12%
Medicine and Dentistry
Multiple Sclerosis
100%
Ocrelizumab
100%
Biological Marker
37%
Clinical Trial
25%
B Cell
25%
Autoimmunity
25%
Diseases
25%
RNA Sequence
12%
Cerebral Atrophy
12%
Cerebrospinal Fluid
12%
Immunocompetent Cell
12%
Placebo
12%
Decision Making
12%
Pathophysiology
12%
Monoclonal Antibody
12%
Patient-Reported Outcome
12%
Disease Course
12%
Cognitive Defect
12%
Neurologic Disease
12%
CD20
12%
Cytotechnology
12%
Screening
12%
Early Intervention
12%
Immune Reconstitution
12%
Placebo-Controlled Study
12%
McDonald Criteria
12%
Cognition
12%
Immunology and Microbiology
Multiple Sclerosis
100%
Ocrelizumab
100%
B Cell
42%
Autoimmunity
28%
Immune Reconstitution
14%
Cerebrospinal Fluid
14%
Immunocompetent Cell
14%
Monoclonal Antibody
14%
RNA Sequence
14%
CD20
14%
Screening
14%
Decision Making
14%
Primary Progressive Multiple Sclerosis
14%
McDonald Criteria
14%
Cognition
14%
Neuroscience
Multiple Sclerosis
100%
Ocrelizumab
100%
B Cell
42%
Placebo
28%
Cognitive Disorders
14%
Monoclonal Antibody
14%
Intrathecal
14%
Cognitive Function
14%
Decision-Making
14%
RNA Sequence
14%
Brain Lesion
14%
Primary Progressive Multiple Sclerosis
14%
CD20
14%